Syndax Pharmaceuticals | 8-K: Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals | DEF 14A: Definitive information statements
Syndax Pharmaceuticals | DEFA14A: Others
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Syndax Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Syndax Pharmaceuticals | 8-K: Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Current report
Syndax Pharmaceuticals | 8-K: Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals | DEFA14A: Others
Syndax Pharmaceuticals | DEFA14A: Others
Syndax Pharmaceuticals | DEF 14A: Definitive proxy statements
No Data